Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Progenics Pharma (PGNX) Misses Q3 EPS by 3c
November 7, 2016 7:56 AM ESTProgenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.52, $0.03 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $53.9 million versus the consensus estimate of $52.9 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... More